RT Conference Proceedings
T1 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC
A1 Garassino, M.
A1 Cho, B. C.
A1 Kim, J.
A1 Mazieres, J.
A1 Vansteenkiste, J.
A1 Lena, H. H.
A1 Corral, J.
A1 Gray, J.
A1 Powderly, J.
A1 Chouaid, C.
A1 Bidoli, P.
A1 Wheatley-Price, P.
A1 Park, K.
A1 Soo, R.
A1 Huang, Y.
A1 Wadsworth, C.
A1 Dennis, P.
A1 Rizvi, N.
K1 durvalumab
K1 programmed cell death ligand-1
K1 Immunotherapy
PB Elsevier science inc
SN 1556-0864
YR 2018
FD 2018-10-01
LK https://hdl.handle.net/10668/27250
UL https://hdl.handle.net/10668/27250
LA en
DS RISalud
RD Apr 19, 2025